KYORIN Pharmaceutical Co., Ltd. (TSE: 4569)
Health Care · Pharmaceuticals · JP
¥1,158.00
+3.58% today · -26.0% 1Y
KYORIN Pharmaceutical Co., Ltd. (TSE: 4569) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $418.45M and employs 1,982 people.
Over the last twelve months the share price has lost 26.0%, trading between 1.05K and 1.73K.
Tweenvest scores KYORIN Pharmaceutical Co., Ltd. across four factors: quality 74/100, value 43/100, growth 15/100, dividend 83/100. Its strongest factor is dividend.
4569 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $418.45M
- Revenue (TTM)
- $773.21M
- P/E
- 30.63
- EPS
- 37.81
- Dividend yield
- 2.16%
- Beta (5Y)
- -0.04
- 52-week high
- ¥1,725.00
- 52-week low
- ¥1,052.00
- Avg volume (3M)
- —
- Shares outstanding
- 57.45M
- Employees
- 1,982
- Next earnings
- —
About KYORIN Pharmaceutical Co., Ltd.
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
- ISIN
- JP3247090008
- Founded
- 1923
- Listed since
- Jan 4, 2001
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.